✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Glenmark Pharmaceuticals Ltd.

GLENMARK

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹58,828 Cr.
P/E
78.05

Glenmark Pharmaceuticals Ltd.

  • Glenmark Pharma
  • Alkem Laboratories
  • Aurobindo Pharma
  • TJI Pharma
FAQs on Glenmark Pharmaceuticals Ltd. Shareprice

Glenmark Pharma has given better returns compared to its competitors.
Glenmark Pharma has grown at ~43.29% over the last 4yrs while peers have grown at a median rate of 10.24%

Yes, Glenmark Pharma is expensive.
Latest PE of Glenmark Pharma is 78.05, while 3 year average PE is 19.32.
Also latest EV/EBITDA of Glenmark Pharma is 25.31 while 3yr average is 14.38.

View FAQ's On Business
Growth Table
  • Glenmark Pharmaceuticals Ltd.
  • Alkem Laboratories
  • Aurobindo Pharma
Balance Sheet
  • Glenmark Pharmaceuticals Ltd.
  • Alkem Laboratories
  • Aurobindo Pharma
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Glenmark Pharmaceuticals Ltd.
  • Alkem Laboratories
  • Aurobindo Pharma
Cash Flow
  • Glenmark Pharmaceuticals Ltd.
  • Alkem Laboratories
  • Aurobindo Pharma
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Glenmark Pharmaceuticals Ltd.
  • Alkem Laboratories
  • Aurobindo Pharma
Quarterly Results
  • Glenmark Pharmaceuticals Ltd.
  • Alkem Laboratories
  • Aurobindo Pharma
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Glenmark Pharmaceuticals Ltd. Financials

Balance sheet of Glenmark Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Glenmark Pharma is increasing.
Latest net debt of Glenmark Pharma is -₹1,215.19 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹2,327.34 Crs.

The profit is oscillating.
The profit of Glenmark Pharma is ₹754 Crs for TTM, ₹1,047 Crs for Mar 2025 and -₹1,501.67 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Glenmark Pharma latest dividend payout ratio is 6.74% and 3yr average dividend payout ratio is 15.23%

Companies resources are allocated to majorly unproductive assets like Inventory, Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech